Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

NCT02737059 | Completed Phase 1 FDA Drug

• 2 other identifiers: 15-007863UL1TR000135
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

This research study was being done to study the effect of codeine and Naloxegol for 3 days compared to placebo on the movement of food through the colon of healthy individuals. Codeine is a commonly used pain-relieving drug that often causes constipation as an unwanted side effect. Naloxegol is a medication recently approved by the FDA for treatment of constipation induced by Codeine. The hypothesis for this study was that Naloxegol reduces the retardation of small bowel and colonic transit induced by codeine in healthy participants.

Conditions

Constipation Drug Induced

Outcome Measures

Primary Outcomes (3)

• Gastric emptying (t1/2)

  The time for half of the ingested solids or liquids to leave the stomach.

  Day 2

• Colonic filling (%) at 6 hours

  Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.

  Day 2 (6 hours)

• Colonic geometric center (GC) at 24 hours

  The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

  Day 2 ( 24 hours)

Secondary Outcomes (2)

• Colonic transit summarized by GC at 48 hours hours hours colonic transit summarized by GC at 4 and 48 hours Colonic transit at 4 and 48 hours

  Day 2 (48 hours)

• Ascending Colon Emptying (ACE) T1/2

  Day 2

Study Arms (4)

Codeine/naloxegol placebo

PLACEBO COMPARATOR

Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement. Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d.

Drug: Codeine; Drug: naloxegol placebo

Naloxegol/ codeine placebo

PLACEBO COMPARATOR

Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement. Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d.

Drug: Naloxegol; Drug: codeine placebo

Codeine/ naloxegol

ACTIVE COMPARATOR

Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement. Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d.

Drug: Naloxegol; Drug: Codeine

codeine placebo/ naloxegol placebo

ACTIVE COMPARATOR

Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement. Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d.

Drug: codeine placebo; Drug: naloxegol placebo

Interventions

Naloxegol DRUG

25mg daily

Also known as: MOVANTIK

Codeine/ naloxegol; Naloxegol/ codeine placebo

Codeine DRUG

30mg 4 times daily

Codeine/ naloxegol; Codeine/naloxegol placebo

codeine placebo DRUG

4 times daily (placebo will be made to match the codeine)

Naloxegol/ codeine placebo; codeine placebo/ naloxegol placebo

naloxegol placebo DRUG

placebo will match naloxegol, given daily

Codeine/naloxegol placebo; codeine placebo/ naloxegol placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Body Mass Index (BMI) between 19 and 30 kg/m\^2 and absolute weight between 45 and 100 kg. for both males and females.
• Females who are non-pregnant, non-lactating, postmenopausal for at least one year (as evidenced by last menses 12 months from Day 0), surgically sterile, or willing to use a clinically-approved method of contraception from 35 days prior to Day 0 until 30 days after the last dose of study medication
• Males who are surgically sterile or willing to use a clinically approved method of contraception from Day 0 until 30 days after the last dose of study medication.
• Absence of gastrointestinal symptoms unless deemed not clinically significant by the Investigator.
• Able to understand and willing to sign informed consent
• Negative urine drug screen at screening

You may not qualify if:

• Structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders. For screening, three or more "YES" responses on the Bowel Disease Questionnaire will be used to exclude subjects with irritable bowel syndrome.
• Use of drugs or agents within the past 2 weeks or planned use in the subsequent 4 weeks during the study period that: Alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetic, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, Selective serotonin re-uptake inhibitors (SSRI) and newer antidepressants.
• Analgesic drugs including opiates, NSAID, cyclooxygenase-2 (COX 2) inhibitors
• Use of non-prescription or prescription medications within 7 days or within five half-lives prior to Day 0 for that particular medication. Note: Low stable doses of thyroid replacement, estrogen replacement, and birth control pills or depot injections, and use of acetaminophen on as needed basis are permissible.
• A score of greater than or equal to 11 for either score obtained from the Hospital Anxiety Depression Scale
• Positive urine drug screen at screening
• Female subjects who are pregnant or breast feeding.
• Clinical evidence (including physical exam, previous laboratory tests) or significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Patients with previously high transaminase levels (AST, ALT) may be retested and if the results are less than 1.5 times the upper limit of normal will be included as long as they do not have an underlying known liver disease.
• Symptoms of a significant clinical illness in the preceding two weeks.
• Participation in another clinical study within the past 30 days.
• Subjects known allergy or hypersensitive to multiple drug compounds (greater than or equal to 3 drug compounds), naloxegol or opioid antagonists, codeine sulfate, eggs or any components of the study medication
• Daily use of any tobacco products within 6 months prior to Day 0
• Previous exposure to naloxegol
• Any other conditions or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study
• Contraindications to use of naloxegol in accordance with FDA guidance: suspected GI obstruction or at increased risk of recurrent obstruction; concomitant use of strong CYP3A4 inhibitors such as clarithromycin and ketoconazole

Sponsors & Collaborators

• Michael Camilleri: lead
• AstraZeneca: collaborator

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Interventions

naloxegol; Codeine

Intervention Hierarchy (Ancestors)

Morphine Derivatives; Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Study Officials

• Michael Camilleri, MD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD, Consultant, Professor of Medicine

Study Record Dates

• First Submitted: April 8, 2016
• First Posted: April 13, 2016
• Study Start: July 1, 2016
• Primary Completion: May 10, 2017
• Study Completion: May 10, 2017
• Last Updated: August 30, 2017

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)